



DRUG (S)	Odactra (house dust mite allergen extract)
Policy#	12129
Indications	Odactra is an allergen extract indicated for adults 18 to 65 years of age, as immunotherapy for the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis, confirmed by in vitro testing for IgE antibodies to <i>Dermatophagoides farinae</i> or <i>Dermatophagoides pteronyssinus</i> house dust mites, or skin testing to licensed house dust mite allergen extracts.
CRITERIA	 ConnectiCare considers Odactra to be medically necessary for patients who meet all of the following criteria: Medication is prescribed by an allergy specialist (allergist, immunologist, or pulmonologist) Patient is 18 to 65 years of age Patient has clinically documented allergic rhinitis with or without conjunctivitis Diagnosis has been confirmed by a positive skin test or in vitro testing for house dust mite-specific IgE antibodies Patient must have at least one nasal corticosteroids for allergic rhinitis that has been ineffective, not tolerated, or contraindicated (e.g. fluticasone) Patient must have at least one other oral medication for allergic rhinitis that has been ineffective, not tolerated, or contraindicated (e.g. loratadine, desloratadine, fexofenadine, levocetirizine, cetirizine, montelukast)
LIMITATIONS	If the above criteria are met approval will be granted for up 12 weeks. Subsequent approval will be based on current progress notes from the physician documenting efficacy. Odactra is contraindicated in the following: 1. Severe, unstable, or uncontrolled asthma 2. History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy 3. History of eosinophilic esophagitis
REFERENCES	1. Odactra [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; April 2017.
P&T REVIEW HISTORY	5/18, 5/19
REVISION RECORD	5/18, 5/19